📊 MIST Key Takeaways
Is Milestone Pharmaceuticals Inc. (MIST) a Good Investment?
Milestone Pharmaceuticals is a pre-revenue or early-stage clinical biotech with severe cash burn (-$49.3M operating FCF) and negative profitability across all metrics (ROE -151%, ROA -55.5%, Net Income -$63.1M). While the company maintains adequate liquidity (8x current ratio, $73M cash), the substantial long-term debt ($57.2M) and lack of revenue generation create an unsustainable financial trajectory without successful product commercialization or significant capital infusion.
Milestone Pharmaceuticals shows the classic profile of a pre-revenue biotech with no operating income, persistent net losses, and materially negative free cash flow. While liquidity is currently strong with $73.05M in cash and high current/quick ratios, the combination of a roughly $49M annual operating cash burn and $57.19M of long-term debt creates meaningful financing and balance-sheet risk if commercialization or regulatory progress is delayed.
Why Buy Milestone Pharmaceuticals Inc. Stock? MIST Key Strengths
- Strong liquidity position with $73M cash and 8.01x current ratio providing near-term runway
- Low current liabilities relative to current assets suggests adequate short-term financial flexibility
- 11 Form 4 insider filings in last 90 days indicate ongoing executive engagement
- Strong near-term liquidity with 8.01x current ratio and $73.05M cash balance
- Asset base still exceeds liabilities, leaving positive stockholders' equity of $41.77M
- Net loss was essentially stable year over year, suggesting some cost containment versus a worsening loss profile
MIST Stock Risks: Milestone Pharmaceuticals Inc. Investment Risks
- Zero revenue with -$62.1M operating loss indicates no commercial success and complete dependence on capital markets
- Annual cash burn of -$49M with deteriorating diluted EPS (-$0.75, -11.9% YoY) suggests accelerating losses
- High debt-to-equity ratio (1.37x) combined with negative interest coverage (-71.3x) creates significant refinancing and solvency risk
- Negative ROE (-151%) and ROA (-55.5%) indicate destruction of shareholder capital at an accelerating rate
- No gross profit or operating margin data reflects absence of commercialized products and revenue generation ability
- No revenue base, leaving the business fully dependent on external funding and pipeline execution
- Heavy cash burn with negative operating cash flow of $49.04M and free cash flow of $49.34M
- Leverage is meaningful for a loss-making company, with debt/equity of 1.37x and negative interest coverage
Key Metrics to Watch
- Path to revenue and timing of product commercialization success
- Cash burn rate and runway before capital requirement (current ~18 months at current burn)
- Clinical trial progress and regulatory approval milestones for lead candidates
- Debt covenant compliance and ability to refinance or service $57.2M long-term debt
- Cash runway relative to quarterly operating cash burn
- Revenue generation or regulatory/commercial milestones that can validate the path to profitability
Milestone Pharmaceuticals Inc. (MIST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.01x current ratio provides a solid financial cushion.
MIST Profit Margin, ROE & Profitability Analysis
MIST vs Healthcare Sector: How Milestone Pharmaceuticals Inc. Compares
How Milestone Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Milestone Pharmaceuticals Inc. Stock Overvalued? MIST Valuation Analysis 2026
Based on fundamental analysis, Milestone Pharmaceuticals Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Milestone Pharmaceuticals Inc. Balance Sheet: MIST Debt, Cash & Liquidity
MIST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Milestone Pharmaceuticals Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.67 indicates the company is currently unprofitable.
MIST Revenue Growth, EPS Growth & YoY Performance
Milestone Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
MIST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Milestone Pharmaceuticals Inc. (CIK: 0001408443)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MIST
What is the AI rating for MIST?
Milestone Pharmaceuticals Inc. (MIST) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIST's key strengths?
Claude: Strong liquidity position with $73M cash and 8.01x current ratio providing near-term runway. Low current liabilities relative to current assets suggests adequate short-term financial flexibility. ChatGPT: Strong near-term liquidity with 8.01x current ratio and $73.05M cash balance. Asset base still exceeds liabilities, leaving positive stockholders' equity of $41.77M.
What are the risks of investing in MIST?
Claude: Zero revenue with -$62.1M operating loss indicates no commercial success and complete dependence on capital markets. Annual cash burn of -$49M with deteriorating diluted EPS (-$0.75, -11.9% YoY) suggests accelerating losses. ChatGPT: No revenue base, leaving the business fully dependent on external funding and pipeline execution. Heavy cash burn with negative operating cash flow of $49.04M and free cash flow of $49.34M.
What is MIST's revenue and growth?
Milestone Pharmaceuticals Inc. reported revenue of N/A.
Does MIST pay dividends?
Milestone Pharmaceuticals Inc. does not currently pay dividends.
Where can I find MIST SEC filings?
Official SEC filings for Milestone Pharmaceuticals Inc. (CIK: 0001408443) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIST's EPS?
Milestone Pharmaceuticals Inc. has a diluted EPS of $-0.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Milestone Pharmaceuticals Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIST stock overvalued or undervalued?
Valuation metrics for MIST: ROE of -151.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIST stock in 2026?
Our dual AI analysis gives Milestone Pharmaceuticals Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIST's free cash flow?
Milestone Pharmaceuticals Inc.'s operating cash flow is $-49.0M, with capital expenditures of $302.0K.
How does MIST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -151.0% (avg: 15%), current ratio 8.01 (avg: 2).